Statins: Can we advocate them for primary prevention of heart disease?
The discovery of cholesterol-lowering agents, namely HMG-CoA reductase inhibitors or statins, ushered in a series of large cholesterol reduction trials. The first of these studies was the Scandinavian Simvastatin Survival Study (4S) in which hypercholesterolemic men with CHD who were treated with simvastatin had a reduction in major coronary events of 44% and a reduction in total mortality of 30%. Many more secondary prevention trials followed to establish unequivocally the benefit of cholesterol reduction. Strategies that aim to improve primary prevention are important for managing the overall burden of disease. Recently therefore, the role of statin in primary prevention is being debated. The JUPITER trial and more recently the Cholesterol Treatment Trialists collaborators, proved that incidences of first major cardiovascular events in apparently healthy individuals were reduced by statins. Statins have also been discussed to be having certain pleiotropic effects on other diseases like diabetes, cancer and osteoporosis. However, issues of cost effectiveness and adverse effects like myositis, and transaminitis still loom large. The medical community needs to debate and evolve a possible consensus on the path breaking subject.
Associate Professor, Dept of Community Medicine, Armed Forces Medical College, Pune 411040, India.
Sougat
S
Ray
Professor, Dept of Community Medicine, Armed Forces Medical College, Pune 411040, India.
A K
AK
Jindal
Classified Specialist (Medicine and Cardiology), Military Hospital, Jalandhar, India.
S
S
Sengupta
Associate Professor, Dept of Pharmacology, Armed Forces Medical College, Pune 411040, India.
S
S
Sinha
Heart disease; Primary prevention; Statins